- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 720689, 10 pages
Regulatory Role of GSK-3β on NF-κB, Nitric Oxide, and TNF-α in Group A Streptococcal Infection
1Department of Internal Medicine, National Cheng Kung University Medical College, Tainan 701, Taiwan
2Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan 701, Taiwan
3Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan 701, Taiwan
4Center of Infectious Disease and Signaling Research, National Cheng Kung University Medical College, Tainan 701, Taiwan
5Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan 701, Taiwan
6Department of Nursing, I-Shou University, Kaohsiung 840, Taiwan
Received 27 October 2012; Revised 20 January 2013; Accepted 24 January 2013
Academic Editor: I-Ming Jou
Copyright © 2013 Yu-Tzu Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Group A streptococcus (GAS) imposes a great burden on humans. Efforts to minimize the associated morbidity and mortality represent a critical issue. Glycogen synthase kinase-3β (GSK-3β) is known to regulate inflammatory response in infectious diseases. However, the regulation of GSK-3β in GAS infection is still unknown. The present study investigates the interaction between GSK-3β, NF-κB, and possible related inflammatory mediators in vitro and in a mouse model. The results revealed that GAS could activate NF-κB, followed by an increased expression of inducible nitric oxide synthase (iNOS) and NO production in a murine macrophage cell line. Activation of GSK-3β occurred after GAS infection, and inhibition of GSK-3β reduced iNOS expression and NO production. Furthermore, GSK-3β inhibitors reduced NF-κB activation and subsequent TNF-α production, which indicates that GSK-3β acts upstream of NF-κB in GAS-infected macrophages. Similar to the in vitro findings, administration of GSK-3β inhibitor in an air pouch GAS infection mouse model significantly reduced the level of serum TNF-α and improved the survival rate. The inhibition of GSK-3β to moderate the inflammatory effect might be an alternative therapeutic strategy against GAS infection.
Group A streptococcus (GAS; Streptococcus pyogenes) is an important clinical pathogen in humans and induces a wide spectrum of clinical presentations including pharyngitis, erysipelas, necrotizing fasciitis, toxic shock syndrome, sepsis, and even mortality . Numerous virulence factors of GAS, including surface molecules such as M protein, hyaluronic acid capsule, and C5a peptidase, or exotoxins, such as pyrogenic exotoxins, streptokinase, hyaluronidase, and streptolysins O and S, enable bacteria to resist phagocytosis in macrophages, escape from complement-mediated destruction, retard the influx of inflammatory cells, or trigger overreaction of immune system [2–6]. Despite advanced supportive care and effective antibiotic treatment, invasive GAS diseases are still responsible for at least 163,000 deaths each year in the world [2, 7, 8]. These facts highlight the urgent need for therapeutic strategies beyond effective antibiotic treatment. In patients with acute invasive GAS infection, the magnitude of elevation of IL-6 and TNF-α is closely related to the severity of systemic manifestations of the disease. Severe invasive cases suffering from toxic shock and/or necrotizing fasciitis have significantly higher frequencies of IL-2-, IL-6-, and TNF-α-producing cells in their circulation as compared to nonsevere invasive cases [9, 10]. Evidence suggests that the induction of cytokine production is, at least in part, due to superantigens of GAS. After the activation by superantigens, production of cytokines (e.g., IL-1, TNF-α, IL-6, and IFN-γ), which mediate shock and tissue injury, is initiated. Streptococcal pyrogenic exotoxin (SPE) B is able to cleave pre-IL-1β to release active form IL-1β . Besides, peptidoglycan, lipoteichoic acid, and killed organisms are capable of inducing TNF production by mononuclear cells in vitro [12, 13]. Thus, clinical management to control the exacerbated inflammatory response caused by GAS infection may diminish collateral tissue damage and further reduce morbidity and mortality.
Glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase, is involved in the regulation of many intracellular functions, including cell division, apoptosis, cell fate during embryonic development, signal pathways stimulated by insulin and many growth factors, and even the dysregulation of disease processes of cancer, diabetes, and neurodegenerative diseases [14–17]. In addition, GSK-3 is critical in either promoting  or repressing  the activity of NF-κB which indicates its possible regulatory role in inflammation. Either GSK-3 inhibitors or siRNA could reduce the production of TNF-α and IL-6 and enhance IL-10 production in monocytes after stimulation by lipopolysaccharide (LPS) . GSK-3β was also shown to regulate the STAT3-mediated IL-6 production in LPS-stimulated glial cells . Furthermore, GSK-3 negatively regulated mycobacterium-induced IL-10 production and the subsequent IFN-γ secretion in monocytes . In animal model of sepsis, treatment with GSK-3 inhibitors could suppress NF-κB-dependent proinflammatory cytokine expression and provide protection from organ injury and endotoxin shock [20, 23, 24]. However, most of the previous studies investigating the role of GSK-3 in infection involved a LPS-induced sepsis model. Few studies have investigated the role of GSK in live bacterial infection, which is more representative of the clinical condition [25–28]. Also, less is known about the role of GSK in Gram-positive bacterial infection.
The macrophage is one of the frontline components in human innate immunity. It plays an important role in clearance of invasive pathogens through phagocytosis. Interference with macrophage function results in higher mortality rate in the GAS-infected animal model . This implies an essential role of macrophages against GAS infection. In search of the possible role of GSK-3β in GAS-induced inflammatory response, we evaluated the activity of GSK-3β and subsequent inflammatory mediators in a mouse macrophage cell line and in the mouse model. Our results demonstrate that GAS infection induces GSK-3β activity, NF-κB nuclear translocation, iNOS expression, and NO and TNF-α production. Inhibition of GSK-3β can negatively regulate the activity of NF-κB and the production of NO and TNF-α. The effects of GSK-3β inhibitor were also observed in GAS-infected mice.
2. Material and Methods
BALB/c mice were purchased from the Jackson Laboratory, Bar Harbor, Maine, and maintained on standard laboratory food and water ad libitum in our animal center. Their progeny, ranging from 8to 10weeks of age, were used for experiments. The animal use protocol had been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC).
2.2. Bacterial Strain
S. pyogenes NZ131 (type M49, T14) was obtained from Dr. D. R. Martin, New Zealand Communicable Disease Center, Porirua. This strain does not contain phage-specific speA and speC genes.
2.3. Air Pouch Model of Infection
In our previous studies, we have established a mouse model of GAS infection using an air pouch [30, 31]. Mice were anesthetized by ether inhalation and then injected subcutaneously with 2 mL of air to form an air pouch on their back. Bacterial suspension was inoculated into the air pouch. Mice infected with GAS developed bacteremia and disseminated into the kidney, liver, and spleen. Mice died within few days (usually 3–7 days) after GAS infection. This model therefore serves as an animal model of sepsis.
2.4. GAS Infection of Macrophages
Mouse macrophage cell line RAW 264.7 was cultured in DMEM with 10% FBS in 5% CO2 at 37°C. RAW 264.7 cells were seeded at 2 × 105/well in 24-well plate containing medium without antibiotics. The next day, NZ131 cultures grown in TSBY were harvested at midlogarithmic phase and added to RAW 264.7 monolayers at different multiplicity of infection (MOI) of 10, 50, and 100. After 60 min of incubation at 37°C, nonadherent extracellular bacteria were eliminated by removing the culture medium and washing by PBS. Adherent extracellular bacteria were subsequently killed by incubation with fresh medium containing 10 μg/mL penicillin G. At specific time points after infection, supernatants were collected for ELISA, and whole cell extracts were prepared for Western blot analysis.
The levels of TNF-α in serum or cell culture supernatant were measured by ELISA kits (R&D system), according to the manufacturer’s instructions. All measurements were carried out in triplicates.
2.6. Western Blot Analysis
Whole cell extracts were separated using SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membrane. After blocking, blots were developed with rabbit antibodies against total and phosphorylated (Ser9) GSK-3β, total GS and phosphorylated (Ser641) GS, and mouse antibodies against iNOS. Mouse antibodies specific for GAPDH or α-tubulin were used for internal control. Finally, blots were hybridized with horseradish-peroxidase- (HRP-) conjugated goat anti-rabbit immunoglobulin G (IgG) or goat anti-mouse IgG, incubation with enhanced chemiluminescence (ECL) solution, and exposure to X-ray film.
2.7. Immunocytochemical Staining
Cells collected at various time points were fixed in 4% formaldehyde for 10 min. Adequately diluted anti-NF-κB p65 antibodies were applied. After reaction with primary antibody at room temperature for 1 h, FITC-labeled secondary antibodies were applied for additional 1 h. DAPI was used for nuclear staining. The positive cells in three fields (under magnification ×200) of each culture were measured.
2.8. NO Analysis
After GAS infection for 24 h with or without GSK-3β inhibitors, supernatant of cell culture was collected. Then, 50 μL Griess reagent was mixed with 50 μL sample for measurement of nitrite level, according to the manufacturer’s instructions.
2.9. Luciferase Reporter Assay
For the NF-κB reporter assay, cells were transiently cotransfected with NF-κB promoter-driven luciferase reporter (0.2 μg) and 0.004 μg of Renilla luciferase-expressing plasmid (pRL-TK; Promega) using the Gene Jammer transfection reagent (Stratagene). At 24 h after the transfection, cells were infected with NZ131 for 1 h and then replaced with medium containing antibiotics. Cells were then harvested for the luciferase assay (Dual-Glo; Promega). The firefly luciferase activity was normalized to the Renilla luciferase activity to evaluate transfection efficiencies.
2.10. Antibody and Reagent
Mouse monoclonal antibody specific for NF-κB p65 was obtained from Chemicon International, Inc. Monoclonal anti-mouse iNOS was from BD Biosciences. Peroxidase-conjugated goat anti-mouse IgG and goat anti-rabbit IgG were from Invitrogen Corp. Antibodies against phospho-GSK-3β (Ser9), GSK-3β, phospho-glycogen synthase (GS) (Ser641), and GS were from Cell Signaling Technology, Inc. Antibody against GAPDH was from Millipore Corporation. Antibody against α-tubulin was from Santa Cruz Biotechnology Inc. Pyrrolidine dithiocarbamate (PDTC), 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) and 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrol-2,5-dione (SB415286) were from Tocris Bioscience. 6-Bromo-indirubin-3′-oxime (BIO), lithium chloride (LiCl) and ammonium chloride (NH4Cl) were from Sigma-Aldrich Co. Blocking antibodies specific for TLR2 and isotype-matched antibody control were from eBioscience, Inc.
2.11. Cell Viability
At 24 h after GAS infection and treatment with or without GSK-3β inhibitors, RAW 264.7 cells were flushed with culture medium in 6-well plates. Then, the whole culture medium was aspirated. The live and dead cells in culture medium were calculated directly under microscope after staining with trypan blue.
2.12. Mouse Survival Rate after GAS Infection
After inoculation with GAS into air pouch, various dosages of GSK-3β inhibitors were injected into the peritoneal cavity at different time points. The survival of mice after infection was observed every 24 h for 10 days.
All statistics were performed using the two-tailed Student’s -test by the software of GraphPad Prism 5.01. The values < 0.05 were considered significant. The mouse survival rate was analyzed by the Kaplan-Meier method.
3.1. GAS Infection Induces the Activation of NF-κB and the Increased Expression of iNOS and NO Production in RAW264.7 Cells
NF-κB is a ubiquitous transcription factor and plays an important role in the host response to pathogenic organisms. The activation of NF-κB can induce the expression of a number of molecules involved in inflammatory response, such as cytokines and iNOS [32, 33]. Infection of human respiratory epithelial cells with GAS induced the activation of NF-κB . To address if infection of macrophages with GAS could also induce the activation of NF-κB, murine macrophage RAW 264.7 cells were infected with GAS NZ131 strain at MOI of 10 for various times. By using immunocytochemical staining and calculating the fold of NF-κB nuclear translocation, the nuclear translocation of NF-κB increased gradually after GAS infection and marked activation of NF-κB was observed 4 h after infection (Figures 1(a) and 1(b)). Similar trend of NF-κB activation was also observed when the activity was measured by luciferase reporter assay (Figure 1(c)).
To further evaluate the expression of iNOS and the subsequent production of NO, we determined the time kinetics and dose response of GAS by Western blotting and Griess reagent. The results revealed that GAS induced the expression of iNOS in a time-dependent manner (Figure 1(d)). The NO production was increased at 12 h with MOI of 50 or 100, and at 24 h with MOI of 10 (Figure 1(e)). To further clarify whether the iNOS expression and NO production were mainly through a NF-κB-dependent pathway, RAW 264.7 cells were treated with GAS in the presence or absence of NF-κB inhibitor, PDTC. Inhibition of NF-κB activity caused suppression of iNOS and NO production (Figures 1(f) and 1(g)). These results reveal an essential role of NF-κB in regulation of iNOS and NO expression in GAS infection.
3.2. GAS Infection Activates GSK-3β and Inhibiting GSK-3β Reduces the Expression of iNOS and the NO Production in RAW264.7 Cells
Since GSK-3β was revealed to act upstream of NF-κB [16, 18, 35, 36], we investigated whether GSK-3β may regulate NF-κB during GAS infection and might be a potential therapeutic target. The dephosphorylation of GSK-3β at serine 9 was observed within 2 h after GAS treatment, which indicates the induced activation of GSK-3β in RAW 264.7 cells after GAS infection (Figure 2(a)). The phosphorylated GS, a GSK-specific substrate, also increased at 2 h after infection (Supplemental Figure in supplementary material available online at http://dx.doi.org/10.1155/2013/720689). These results suggest that GAS infection could induce GSK-3β activation. When RAW 264.7 cells were stimulated with heat-inactivated GAS, there was only slight activation of GSK-3β (Supplemental Figure ).
To further explore the role of GSK-3β, we found that the expression of iNOS was reduced by GSK-3β inhibitors (Figure 2(b)). Although the inhibition of iNOS expression was not apparent with lithium treatment as compared with SB compounds and BIO treatment, the NO production was significantly suppressed by lithium (Figure 2(c)). BIO could efficiently suppress the NO production. When measuring the cell viability under GAS infection with or without GSK-3β inhibition, GAS infection resulted in 29.23% cell death and treatment with GSK-3β inhibitors, lithium and BIO, could improve cell viability (Figure 2(a)). Thus, the reduction of NO production was not due to the reduced cell numbers. These results confirm that GSK-3β activation is involved in GAS infection and inhibition of GSK-3β reduces NO production, which implies the possible therapeutic application in GAS infection.
3.3. Inhibition of GSK-3β Activity Downregulates the NF-κB Activation and TNF-α Production in GAS-Infected RAW 264.7 Cells
To further determine the essential role of GSK-3β in GAS infection, we examined the effect of GSK-3β inhibition on NF-κB activation and TNF-α production. Using immunocytochemistry to detect NF-κB p65 after GAS infection, nuclear translocation of NF-κB was reduced after inhibiting GSK-3β by various inhibitors (Figure 3(a)). The ratio of NF-κB nuclear translocation after GSK-3β inhibitor treatment was even lower than the basal level (Figure 3(b)). To investigate whether TNF-α production was also regulated by NF-κB, we treated RAW 264.7 cells with PDTC under GAS infection. The TNF-α production was significantly suppressed by NF-κB inhibition (Figure 3(c)). This implies that GAS induces TNF-α expression via NF-κB activation. Furthermore, when treated with BIO and lithium, the production of TNF-α was also reduced in GAS infection (Figure 3(d) and Supplemental Figure ). These results indicate that GSK-3β is involved in GAS-induced NF-κB activation and TNF-α production, and inhibition of GSK-3β can lessen the GAS-induced inflammatory response.
3.4. GAS Internalization and TLR-2 Signaling Regulate TNF-α Production and iNOS Expression
GAS is known to survive and replicate in the macrophage and intracellular GAS can mediate NF-κB activity . Besides, cell wall components of Gram-positive bacteria can induce inflammatory response through TLR-2 . We next determined whether GAS invasion or adherence to the plasma membrane can regulate TNF-α and iNOS expression. We found that either inhibition of endocytosis or blocking TLR-2 signaling can partially suppress TNF-α and iNOS expression (Supplemental and ). These results suggest that GAS internalization and TLR-2 signaling may, at least in part, participate in the regulation of GAS-induced inflammatory response.
3.5. Inhibition of GSK-3β Activity Provides Protection of Sepsis Induced by GAS and Suppresses Serum TNF-α Level in Mouse Model
Since the inhibition of GSK-3β led to reduced NF-κB activation and TNF-α production in vitro, we next determined whether this protective effect via GSK-3β inhibition could be observed in vivo. Administration of lithium, a drug which has been used for bipolar disorder, improved the survival rate in the treated group () (Figure 4(a)). Lithium treatment after GAS infection could significantly suppress TNF-α production (Figure 4(b)). Thus, inhibition of GSK-3β could reduce the level of TNF-α and increase survival in the GAS-induced sepsis model.
Group A streptococcus is an important human pathogen and carries a high clinical burden worldwide . Reducing the related complications and mortality and morbidity caused by GAS infection remains a critical issue. GSK-3, a key enzyme in glycogen metabolism, is involved in many intracellular functions . In recent studies of shock and inflammation [16, 20, 23, 36], GSK-3β inhibitors can not only suppress the production of proinflammatory cytokines but also increase anti-inflammatory cytokines. GSK-3β inhibitors also provide a survival advantage and can attenuate organ injury in animal models of sepsis. However, the protective effect of GSK-3β inhibition was mostly demonstrated in LPS-induced sepsis models and only a few studies explored the possible effect of GSK-3β inhibition against live bacteria, which is more similar to clinical conditions . In the present work, we proved that GAS infection induced the activation of GSK-3β and increased nuclear translocation of NF-κB, as well as iNOS expression and NO and TNF-α production. Inhibiting the activity of GSK-3β was able to downregulate the activation of NF-κB and suppress the subsequent inflammatory mediators, including iNOS, NO, and TNF-α induced by GAS infection. This result is also consistent with previous findings that GSK-3β acts upstream of NF-κB [16, 18, 35, 36] and the present study indicates that GAS activates macrophages through a GSK-3β-NF-κB-dependent pathway (Figure 5). Previous report showed that heat-inactivated Staphylococcus aureus could also mediate GSK-3β activity . In the present study, the GSK-3β activity was only slightly increased after stimulation with heat-inactivated GAS (Supplemental Figure ). Whether GAS-induced GSK-3β activity could be related to some secreted proteins, in addition to cell wall components, remains to be explored. Furthermore, the identities of the upstream molecules or even the recognition receptor are not clear. Previous studies [40, 41] indicated that the recognition of GAS and subsequent signal transduction was MyD88 dependent. Thus, further studies are needed to clarify this crosstalk between GSK-3β and MyD88 and NF-κB.
GSK-3β is known to regulate the main eukaryotic transcription factor NF-κB, which is involved in many intracellular processes. After activation of NF-κB, its subunit of p50/p65 translocates from cytoplasm to the nucleus and initiates target gene transcription, including proinflammatory cytokines, chemokines, adhesion molecules, matrix metalloproteases (MMPs), and iNOS [42–44]. Various reports [16, 20, 45, 46] have shown that GSK-3β is able to affect NF-κB activity by several different mechanisms: (1) through phosphorylation of IκB, (2) facilitating translocation of p50/p65 to the nucleus and the binding to DNA, (3) phosphorylation of p65, or (4) through CREB. In our present work, we proved that NF-κB plays an important role in GAS-induced inflammatory responses. After treatment with various GSK-3β inhibitors in GAS-infected RAW 264.7 cells, the ratio of nuclear translocation of NF-κB decreased and the levels were even lower than the noninfected group. NF-κB is known to mediate many proinflammatory responses during bacterial infection , including GAS . Our results indicate that NF-κB play a central role in regulation of TNF-α and iNOS expression. We also found that GSK-3β, GAS internalization, and TLR-2 all mediate TNF-α and iNOS expression. The detailed mechanism of the interrelationship between GSK-3β, GAS internalization, and TLR-2 signaling leading to NF-κB activation remains to be clarified.
In the LPS-induced sepsis model, GSK-3β phosphorylation at Ser9 was found to be initially reduced but recovered to baseline level after a short period of time [47–49]. In contrast, our data revealed prolonged dephosphorylation of GSK-3β at Ser9 even 24 h after stimulation by GAS. We found that production of TNF-α and NO persisted 24 h after infection. TNF-α plays a critical role in modulating the cytokine cascade and the fate of macrophages . Deletion of TNF receptor p60 or p80 facilitates LPS-induced apoptosis  but desensitizes Fas ligand-induced apoptosis . The dual role of NO in regulation of inflammation is also recognized. Different levels of NO production or the duration to NO exposure are detrimental factors in mediating the degree of inflammation and tissue injury . The pathophysiological role of persistent activation of GSK-3β in GAS-stimulated macrophages and the regulation of subsequent inflammatory reactions and cell fate still need further investigation.
Sepsis is a complex interaction between pathogen and host. Sepsis is characterized as the burst production of cytokines, chemokines, and NO. The transcription of these proinflammatory markers occurs mainly through the activation of NF-κB and leads to subsequent tissue hypoperfusion, organ injury, and dysregulation of the coagulation system . In patients with GAS infection, higher circulation level of cytokines, such as TNF-α and IL-6, also correlated with the disease severity . Thus, blockade of the activity of NF-κB and the production of proinflammatory mediators might prevent further morbidity and mortality of sepsis. In clinical trials targeting proinflammatory cytokines, such as TNF-α or IL-1β, in patients with sepsis have not yielded the desirable outcomes [55–57]. In previous studies, the administration of GSK-3β inhibitors revealed promising benefits for survival in animal models [16, 20, 23, 36]. In the present study, we also show that GSK-3β inhibition provides survival benefit in GAS infection. Live bacterial infection involves the multiplication of bacteria, the production of multiple exotoxins and the various evoked inflammatory pathway after infection. The GAS strain we used is a SPE B-producing strain which could cause the dysregulation of host immune system and facilitate invasion of bacteria . If treatment of GSK-3β inhibitors can only suppress the production of proinflammatory cytokines without also blocking SPE B-induced pathogenic effects, persistent replication and dissemination of bacteria would be expected and this will lessen the therapeutic effect of GSK-3β inhibitor. However, due to the pleiotropic effect of GSK-3β inhibition including anti-inflammation, antiapoptosis, and tissue regeneration , GSK-3β inhibition may be a superior therapeutic strategy to those utilizing monoclonal antibody antagonists in the management of sepsis in combination with antibiotic treatment.
In conclusion, GAS infection in macrophages can mediate the activation of the GSK-3β-NF-κB signaling pathway and the subsequent production of TNF-α and NO. Inhibition of GSK-3β can downregulate NF-κB and its associated inflammatory response. In animal model studies, GSK-3β inhibition can reduce TNF-α production and lower the mortality when compared to a control group. Since GSK-3β inhibition can provide anti-inflammatory effects in vitro and in vivo, it could offset cytokine storm-related tissue injury during sepsis and might therefore act as an alternative therapeutic strategy beyond antibiotic treatment.
Conflict of Interests
No conflict of interests should be declared.
The authors thank Dr. Robert Anderson for the critical reading of this paper. This work is supported by Grants of NCKUH-10105009 (to Y.-T. Chang) from the National Cheng Kung University Hospital and of NSC 101-2320-B-006-021-MY3 (to Y.-S. Lin) from the National Science Council, Taiwan.
- M. W. Cunningham, “Pathogenesis of group a streptococcal infections,” Clinical Microbiology Reviews, vol. 13, no. 3, pp. 470–511, 2000.
- J. M. Musser and S. A. Shelburne, “A decade of molecular pathogenomic analysis of group A Streptococcus,” Journal of Clinical Investigation, vol. 119, no. 9, pp. 2455–2463, 2009.
- J. N. Cole, T. C. Barnett, V. Nizet, and M. J. Walker, “Molecular insight into invasive group A streptococcal disease,” Nature Reviews Microbiology, vol. 9, no. 10, pp. 724–736, 2011.
- J. B. Dale, R. G. Washburn, M. B. Marques, and M. R. Wessels, “Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci,” Infection and Immunity, vol. 64, no. 5, pp. 1495–1501, 1996.
- K. Berggård, E. Johnsson, E. Morfeldt, J. Persson, M. Stålhammar-Carlemalm, and G. Lindahl, “Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes,” Molecular Microbiology, vol. 42, no. 2, pp. 539–551, 2001.
- Y. Ji, L. McLandsborough, A. Kondagunta, and P. P. Cleary, “C5a peptidase alters clearance and trafficking of group A streptococci by infected mice,” Infection and Immunity, vol. 64, no. 2, pp. 503–510, 1996.
- J. R. Carapetis, A. C. Steer, E. K. Mulholland, and M. Weber, “The global burden of group A streptococcal diseases,” The Lancet Infectious Diseases, vol. 5, no. 11, pp. 685–694, 2005.
- D. L. Stevens, “Invasive group A Streptococcus infections,” Clinical Infectious Diseases, vol. 14, no. 1, pp. 2–11, 1992.
- A. Norrby-Teglund, S. Chatellier, D. E. Low, A. McGeer, K. Green, and M. Kotb, “Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection,” European Journal of Immunology, vol. 30, no. 11, pp. 3247–3255, 2000.
- A. Norrby-Teglund, K. Pauksens, M. Norgren, and S. E. Holm, “Correlation between serum TNFα and IL6 levels and severity of group A streptococcal infections,” Scandinavian Journal of Infectious Diseases, vol. 27, no. 2, pp. 125–130, 1995.
- V. Kapur, M. W. Majesky, L. L. Li, R. A. Black, and J. M. Musser, “Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 16, pp. 7676–7680, 1993.
- H. Muller-Alouf, J. E. Alouf, D. Gerlach, J. H. Ozegowski, C. Fitting, and J. M. Cavaillon, “Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide,” Infection and Immunity, vol. 62, no. 11, pp. 4915–4921, 1994.
- S. P. Hackett and D. L. Stevens, “Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-β synthesis,” Journal of Infectious Diseases, vol. 168, no. 1, pp. 232–235, 1993.
- S. Frame and P. Cohen, “GSK3 takes centre stage more than 20 years after its discovery,” Biochemical Journal, vol. 359, no. 1, pp. 1–16, 2001.
- P. Cohen and S. Frame, “The renaissance of GSK3,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 769–776, 2001.
- L. Dugo, M. Collin, and C. Thiemermann, “Glycogen synthase kinase 3β as a target for the therapy of shock and inflammation,” Shock, vol. 27, no. 2, pp. 113–123, 2007.
- R. S. Jope, C. J. Yuskaitis, and E. Beurel, “Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics,” Neurochemical Research, vol. 32, no. 4-5, pp. 577–595, 2007.
- K. P. Hoeflich, J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett, “Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation,” Nature, vol. 406, no. 6791, pp. 86–90, 2000.
- K. Saijo, B. Winner, C. T. Carson et al., “A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death,” Cell, vol. 137, no. 1, pp. 47–59, 2009.
- M. Martin, K. Rehani, R. S. Jope, and S. M. Michalek, “Toll-like receptor—mediated cytokine production is differentially regulated by glycogen synthase kinase 3,” Nature Immunology, vol. 6, no. 8, pp. 777–784, 2005.
- E. Beurel and R. S. Jope, “Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain,” Journal of Neuroinflammation, vol. 6, article 9, 2009.
- M. M. P. Chan, B. K. W. Cheung, J. C. B. Li, L. L. Y. Chan, and A. S. Y. Lau, “A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction,” Journal of Leukocyte Biology, vol. 86, no. 2, pp. 283–291, 2009.
- L. Dugo, M. Collin, D. A. Allen et al., “GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat,” Critical Care Medicine, vol. 33, no. 9, pp. 1903–1912, 2005.
- J. R. Woodgett and P. S. Ohashi, “GSK3: an in-toll-erant protein kinase?” Nature Immunology, vol. 6, no. 8, pp. 751–752, 2005.
- T. J. Cremer, P. Shah, E. Cormet-Boyaka, M. A. Valvano, J. P. Butchar, and S. Tridandapani, “Akt-mediated proinflammatory response of mononuclear phagocytes infected with Burkholderia cenocepacia occurs by a novel GSK3β-dependent, IκB kinase-independent mechanism,” Journal of Immunology, vol. 187, no. 2, pp. 635–643, 2011.
- P. Zhang, J. Katz, and S. M. Michalek, “Glycogen synthase kinase-3β (GSK3β) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice,” Molecular Immunology, vol. 46, no. 4, pp. 677–687, 2009.
- C. A. D. Burnham, S. E. Shokoples, and G. J. Tyrrell, “Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3,” Microbiology, vol. 153, no. 12, pp. 4240–4252, 2007.
- J. Oviedo-Boyso, R. Cortes-Vieyra, A. Huante-Mendoza, et al., “The phosphoinositide-3-kinase-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells,” ,Infection and Immunity, vol. 79, no. 11, pp. 4569–4577, 2011.
- O. Goldmann, M. Rohde, G. S. Chhatwal, and E. Medina, “Role of macrophages in host resistance to group A streptococci,” Infection and Immunity, vol. 72, no. 5, pp. 2956–2963, 2004.
- C. F. Kuo, J. J. Wu, K. Y. Lin et al., “Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection,” Infection and Immunity, vol. 66, no. 8, pp. 3931–3935, 1998.
- C. F. Kuo, Y. H. Luo, H. Y. Lin et al., “Histopathologic changes in kidney and liver correlate with streptococcal pyrogenic exotoxin B production in the mouse model of group A streptococcal infection,” Microbial Pathogenesis, vol. 36, no. 5, pp. 273–285, 2004.
- S. Ghosh, M. J. May, and E. B. Kopp, “NF-κB and rel proteins: evolutionarily conserved mediators of immune responses,” Annual Review of Immunology, vol. 16, pp. 225–260, 1998.
- G. Bonizzi and M. Karin, “The two NF-κB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004.
- P. J. Tsai, Y. H. Chen, C. H. Hsueh et al., “Streptococcus pyogenes induces epithelial inflammatory responses through NF-κB/MAPK signaling pathways,” Microbes and Infection, vol. 8, no. 6, pp. 1440–1449, 2006.
- Y. Takada, X. Fang, M. S. Jamaluddin, D. D. Boyd, and B. B. Aggarwal, “Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor,” The Journal of Biological Chemistry, vol. 279, no. 38, pp. 39541–39554, 2004.
- L. Dugo, M. Abdelrahman, O. Murch, E. Mazzon, S. Cuzzocrea, and C. Thiemermann, “Glycogen synthase kinase-3β inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation,” Shock, vol. 25, no. 5, pp. 485–491, 2006.
- E. Hertzén, L. Johansson, R. Wallin et al., “M1 protein-dependent intracellular trafficking promotes persistence and replication of Streptococcus pyogeness in macrophages,” Journal of Innate Immunity, vol. 2, no. 6, pp. 534–545, 2010.
- S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
- Y. L. Cheng, C. Y. Wang, W. C. Huang et al., “Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3β-regulated pathway,” Infection and Immunity, vol. 77, no. 9, pp. 4002–4008, 2009.
- T. G. Loof, O. Goldmann, and E. Medina, “Immune recognition of Streptococcus pyogenes by dendritic cells,” Infection and Immunity, vol. 76, no. 6, pp. 2785–2792, 2008.
- N. Gratz, M. Siller, B. Schaljo et al., “Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9,” The Journal of Biological Chemistry, vol. 283, no. 29, pp. 19879–19887, 2008.
- Q. Li and I. M. Verma, “NF-κB regulation in the immune system,” Nature Reviews Immunology, vol. 2, no. 10, pp. 725–734, 2002.
- P. A. Baeuerle and V. R. Baichwal, “NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules,” Advances in Immunology, vol. 65, pp. 111–137, 1997.
- P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001.
- S. H. Obligado, O. Ibraghimov-Beskrovnaya, A. Zuk, L. Meijer, and P. J. Nelson, “CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases,” Kidney International, vol. 73, no. 6, pp. 684–690, 2008.
- R. Cortes-Vieyra, A. Bravo-Patino, J. J. Valdez-Alarcon, M. C. Juarez, B. B. Finlay, and V. M. Baizabal-Aguirre, “Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens,” Journal of Inflammation, vol. 9, no. 1, pp. 23–31, 2012.
- W. C. Huang, Y. S. Lin, C. Y. Wang et al., “Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells,” Immunology, vol. 128, no. 1, pp. e275–e286, 2009.
- L. Chen, F. Ren, H. Zhang, et al., “Inhibition of glycogen synthase kinase 3β ameliorates D-GalN/LPS-induced liver injury by reducing endoplasmic reticulum stress-triggered apoptosis,” PLoS ONE, vol. 7, no. 9, Article ID e45202, 2012.
- C. C. Tsai, J. I. Kai, W. C. Huang et al., “Glycogen synthase kinase-3β facilitates IFN-γ-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2,” Journal of Immunology, vol. 183, no. 2, pp. 856–864, 2009.
- N. Parameswaran and S. Patial, “Tumor necrosis factor-α signaling in macrophages,” Critical Reviews in Eukaryotic Gene Expression, vol. 20, no. 2, pp. 87–103, 2010.
- Y. Takada and B. B. Aggarwal, “Genetic deletion of the tumor necrosis factor receptor p60 or p80 sensitizes macrophages to lipopolysaccharide-induced nuclear factor-κB, mitogen-activated protein kinases, and apoptosis,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23390–23397, 2003.
- Y. Takada, B. Sung, G. Sethi, M. M. Chaturvedi, and B. B. Aggarwal, “Evidence that genetic deletion of the TNF receptor p60 or p80 inhibits Fas mediated apoptosis in macrophages,” Biochemical Pharmacology, vol. 74, no. 7, pp. 1057–1064, 2007.
- Y. Kobayashi, “The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation,” Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1157–1162, 2010.
- J. A. Russell, “Management of sepsis,” The New England Journal of Medicine, vol. 355, no. 16, pp. 1699–1713, 2006.
- E. Abraham, P. F. Laterre, J. Garbino et al., “Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients,” Critical Care Medicine, vol. 29, no. 3, pp. 503–510, 2001.
- E. Abraham, R. Wunderink, H. Silverman et al., “Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial,” The Journal of the American Medical Association, vol. 273, no. 12, pp. 934–941, 1995.
- C. J. Fisher Jr., J. F. A. Dhainaut, S. M. Opal et al., “Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial,” The Journal of the American Medical Association, vol. 271, no. 23, pp. 1836–1843, 1994.
- C. F. Kuo, J. J. Wu, P. J. Tsai et al., “Streptococcal pyrogenic exotoxin B induces apoptosis and reduces phagocytic activity in U937 cells,” Infection and Immunity, vol. 67, no. 1, pp. 126–130, 1999.